U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N4O5
Molecular Weight 334.3272
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITOMYCIN

SMILES

CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O

InChI

InChIKey=NWIBSHFKIJFRCO-WUDYKRTCSA-N
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H18N4O5
Molecular Weight 334.3272
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
MITOSOL
Palliative
MITOMYCIN
Palliative
MITOMYCIN

AUC

ValueDoseCo-administeredAnalytePopulation
773 μg × h/L
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens
630 μg × h/L
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
54 min
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens
50 min
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
76%
MITOMYCIN plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Sponges provided within the Mitosol ® Kit should be fully saturated with the entire reconstituted contents. A treatment area approximating 10 mm x 6 mm +/- 2 mm should be treated with the Mitosol®.
Route of Administration: Topical
In Vitro Use Guide
The molecular mechanism of differentiation interruption by mitomycin C in the Non-small-cell lung cancer (NSCLC) line A549 was investigated. High dosage of mitomycin C (300 µM) could significantly inhibit cell proliferation (P < 0.05) by 48.39 ± 3.32% (P < 0.05), under which cell shrinkage and disruption were observed
Substance Class Chemical
Record UNII
50SG953SK6
Record Status Validated (UNII)
Record Version